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Inpatientswithcardiovasculardisease(CVD),depressioniscommon,persistent,andassociatedwithworsehealth-relatedqualityof
life, recurrent cardiac events, and mortality. Both physiological and behavioral factors—including endothelial dysfunction, platelet
abnormalities, inflammation, autonomic nervous system dysfunction, and reduced engagement in health-promoting activities—
may link depression with adverse cardiac outcomes. Because of the potential impact of depression on quality of life and cardiac
outcomes,theAmericanHeartAssociationhasrecommendedroutinedepressionscreeningofallcardiacpatientswiththe2-and9-
item Patient Health Questionnaires. However, despite the availability of these easy-to-use screening tools and effective treatments,
depression is underrecognized and undertreated in patients with CVD. In this paper, we review the literature on epidemiology,
phenomenology, comorbid conditions, and risk factors for depression in cardiac disease. We outline the associations between
depression and cardiac outcomes, as well as the mechanisms that may mediate these links. Finally, we discuss the evidence for
and against routine depression screening in patients with CVD and make specific recommendations for when and how to assess
for depression in this high-risk population.
1. Introduction
Depression in cardiac disease is common, persistent, under-
recognized, and deadly. Over the past 20 years, research has
found that not only is depression more common in cardiac
patientsthaninthegeneralpopulation,butdepressionisalso
ariskfactorforcardiacmorbidityandmortality,independent
of traditional risk factors. This link between depression
and cardiac morbidity likely involves both physiologic and
behavioral effects of depression. Fortunately, screening for
depression in cardiac patients is straightforward, and meth-
odsofdiagnosisessentiallyparallelthoseformajordepressive
disorder (MDD) diagnosis in other settings. In this paper, we
w i l lr e v i e wt h ee p i d e m i o l o g y ,c o u r s e ,i m p a c t ,p a t h o g e n e s i s ,
and diagnostic assessment of depression in patients with car-
diovasculardisease(CVD).Wewilldefinedepressionaseither
elevateddepressivesymptomsonavalidateddepressionscale
oraformaldiagnosisofMDD.Ofnote,wewillnotspecifically
address treatment of depression in cardiac patients, a topic
that is worthy of its own separate review and that has been
recently reviewed in detail [1].
2. Prevalence of Depression in
Cardiac Patients
Depression is highly prevalent in cardiac patients. Between
31–45% of patients with coronary artery disease (CAD),
includingthosewithstableCAD,unstableangina,ormyocar-
dial infarction (MI), suffer from clinically significant depres-
sive symptoms [2]. Furthermore, 15–20% of patients with
C A Dm e e tc r i t e r i aa ta n yg i v e nt i m ef o rt h ef u l ls y n d r o m e
of MDD [3–7]; this rate of MDD is roughly threefold higher
thaninthegeneralpopulation[8]andissimilartotheratesof
MDD in patients with chronic kidney disease [9] and cancer
[10].
Patients with heart failure (HF), atrial fibrillation (AF)
and those undergoing implantable cardioverter-defibrillator2 Cardiovascular Psychiatry and Neurology
(ICD) placement are similarly at increased risk for elevated
depressive symptoms and for MDD [11–13]. A meta-analysis
of patients with HF found prevalence rates of 36% for
increased depressive symptoms and 20% for MDD [12].
Furthermore, a recent systematic review of ICD patients
found depressive disorders (e.g., MDD, dysthymic disorder)
to be present in 11–28% of patients [11]. Finally, among
patients undergoing coronary artery bypass graft (CABG)
surgery, approximately 30–40% of patients meet criteria for
dysthymia, minor or major depression, with roughly 15% of
patients meeting full MDD criteria on diagnostic interview
[14].
3. Course of Illness
In patients with CVD, depression is often chronic and
recurrent. Among patients with CVD hospitalized for acute
cardiac events and found to meet criteria for depression
duringorshortlyafteradmission,approximately50–70%had
ongoing depressive symptoms that preceded their cardiac
event [15–17]; this finding is consistent with literature that
describes persistent depression in patients with stable CAD
[18]. Furthermore, rather than being a transient reaction to a
cardiac event, depression for many patients exists for months
or years before and persists long after the event [15–22].
In studies that examine the course of post-MI depression,
depressive symptoms remain at steady levels of severity over
the 12 months after an MI [19, 20]. Similar results have been
observed in patients with chronic CVD, such as those with
ICDs; in this cohort, 80% of patients who are depressed at
thetimeofICDplacementcontinuetosufferfromdepressive
symptoms2yearslater[22].Finally,amongpatientsadmitted
with a HF exacerbation and diagnosed with MDD, less than
half have a remission of symptoms at 5-month followup [21].
In sum, depression is present in a significant portion of
patients across the spectrum of cardiac disease, and such
symptoms, when present, are likely to persist unless treated.
These findings underscore the need to find better methods
for identifying—and managing—depression in patients with
CVD.
4. Risk Factors for Depression in
Cardiac Patients
Though there are some inconsistencies in the literature, there
are several established risk factors for depression in cardiac
patients. Most studies have found that younger patients,
women, and patients with premorbid histories of depression
a r em o r el i k e l yt oh a v ed e p r e s s i o ni nt h ec o n t e x to fC V D
[25–29]. Among patients suffering from an acute coronary
syndrome (ACS), in addition to the previous factors, social
isolation, prior ACS, and in some cases, comorbid diabetes
may also increase depression risk [27, 28, 30–32].
These factors, as well as poor functional status or worse
New York Heart Association (NYHA) HF severity class,
have also been linked to depression in patients with HF
[33–35]. Among CABG patients, depression pre-CABG is
predictedbyfemalegender,youngerage,livingalone,andless
education [36], and post-CABG depression is best predicted,
not surprisingly, by pre-CABG depressive symptoms and
anxiety [37]. Similarly, among patients with an ICD for
ventricular arrhythmias, younger age and female gender
predict depression [11] ;t h e r ei ss o m es u g g e s t i o n ,t h o u g hn o t
definitiveevidence,thatICDshocksarelinkedtohigherrates
of depression [11, 38].
5. Psychiatric Conditions
Commonly Comorbid with Depression in
Cardiac Patients
With respect to comorbid symptoms and conditions, symp-
toms of anxiety and formal anxiety disorders are strongly
correlated with depression in a wide variety of cardiac
populations, as they are in the general population. Elevated
symptoms of anxiety are highly prevalent in cardiac patients,
including those suffering an ACS [39, 40], those with stable
CAD [41], those participating in cardiac rehabilitation [42],
and those hospitalized for one of several different cardiac
conditions [17].
Formalanxietydisordersarefrequentlyseeninarangeof
cardiac patients as well [43]; of these disorders, generalized
anxiety disorder (GAD) is the most common by far. For
example, GAD was concomitantly present in 38% of MDD
cases in a large study of outpatients with CAD [44], and
GAD was commonly comorbid with MDD among patients
suffering an ACS [45].
In addition to GAD, posttraumatic stress disorder
(PTSD) is common among specific populations of depressed
cardiac patients, especially CABG patients and those receiv-
ing ICDs. Among patients undergoing CABG, PTSD occurs
in approximately 15% of patients [14, 46], and a recent trial
f o u n dt h a to v e rh a l fo fp o s t - C A B Gp a t i e n t sw i t hP T S Dh a d
concomitant depression [46]. PTSD is at least common (18–
37% in two identified studies) among patients with an ICD
andiscommonlycomorbidwithdepression[47,48].Inthese
patients,PTSDmaystemfromthecardiaceventnecessitating
ICD placement or from firing of the device itself [49].
Anxiety disorders, especially GAD, may be associated
with mortality and other adverse cardiac outcomes, inde-
pendent of both traditional risk factors and depression
[41, 44, 50, 51], and thus these disorders that are so often
comorbid with depression should also be addressed. There is
controversy regarding whether the effects of GAD and MDD
on cardiac outcome are additive, with some [50], but not all
[41], studies finding additive effects. Assessment for anxiety
symptoms can be completed via the Hospital Anxiety and
DepressionScale(whichhastheadvantageofalsocontaining
a depression subscale), while specific screening for GAD can
be completed using the Generalized Anxiety Disorder-2 [52]
(GAD-2) or Generalized Anxiety Disorder-7 [53]( G A D - 7 )
measures.
6. Association between Depression and
Cardiac Outcomes
A multitude of studies over the past 15 years have confirmed
that depression is associated with adverse cardiovascular
outcomes, independent of traditional risk factors. In healthyCardiovascular Psychiatry and Neurology 3
individuals, depression has been independently associated
with the development and progression of CAD [54–57]
and with CVD-related mortality [58]. In fact, two separate
systematic quantitative reviews have found depression (diag-
nosed with a diagnostic interview or self-report measure)
to be a significant and independent risk factor for the
development of cardiac disease, with a relative risk of 1.6
(relative risk 1.64 [95% Confidence Interval (CI) = 1.41–1.90]
and 1.60 [95% CI 1.34–1.92], resp.) in depressed patients
compared to those persons who were never depressed [56,
59].
Depressed patients with unstable CAD appear to be at
even greater risk for poor cardiac outcomes. The presence
of post-MI depression predicts recurrent cardiac events [60],
cardiac-related death [60–63], and all-cause mortality [60,
64]. Indeed, a recent meta-analysis revealed that depressed
post-MI patients have a 2.4-fold increased risk (unadjusted)
for all-cause mortality (odds ratio 2.38; 95% CI = 1.76–
3.22) [60]. Likewise, among patients with a wider range
of unstable or angiographically validated CAD, a meta-
analysis of 20 studies found depressive symptoms and MDD
to be associated with mortality (Hazard ratio 1.76 [95%
CI = 1.27–2.43], adjusted for other risk factors) in the
two years following an event [64]. Furthermore, depressive
s y m p t o m sf o l l o w i n gM Ih a v eb e e na s s o c i a t e dw i t hi n c r e a s e d
hospitalreadmissions,particularlycardiacreadmissions,and
with reduced adoption of secondary prevention behaviors,
including smoking cessation, physical activity, and cardiac
rehabilitation [65–68].
Regarding the timing of depression onset, a 2012 meta-
analysis found that depression was independently predictive
ofmortalityandcardiacmorbidityafteranACS,regardlessof
whetherthedepressionwaspresentpriortooraftertheonset
of cardiac illness; however, first-onset depression within 30
days of an acute cardiac event was potentially more strongly
linked to morbidity and mortality [69]. Of note, following
an acute cardiac event, prior history of depression, without
currentdepression,wasnotassociatedwithadverseoutcomes
[69].
Depression also appears to substantially impact cardio-
vascular outcomes in patients with other forms of CVD.
Clinicallysignificantdepressionincreasestheriskofincident
HF, especially in those already at increased risk for its
development;inpatientswithestablishedHF,itisalsorelated
to increased health care utilization, more frequent hospi-
talizations, and a 2-fold increase in mortality risk [12, 70].
Increased depressive symptoms are also linked to recurrence
of AF in patients following cardioversion [71]a n dw i t h
cardiovascular mortality in patients with comorbid AF and
HF [72].
In patients undergoing CABG, depression has been asso-
ciatedwithlongerhospitalization[73],poorerfunctionalout-
comes [74, 75], more perioperative complications [73], worse
health-related quality of life (HRQoL) [76], progression of
atherosclerotic disease [77], higher rates of rehospitalization
[75], and mortality [14, 78, 79]. Finally, depression has
been associated with mortality, independent of covariates, in
patients with an ICD [80].
Several studies have evaluated the characteristics of psy-
c h i a t r i ci l l n e s sa n di t st r e a t m e n tt h a tm a yc o n t r i b u t et op o o r
cardiacoutcomesindepressedcardiacpatients.Nonresponse
to treatment for depression, for instance, appears to put
depressed post-ACS patients at greater risk for recurrent
cardiac events [81] and for all-cause mortality [82]. Poor
outcomesmaybeexacerbatedbythepresenceofcooccurring
anxiety, which is independently associated with recurrent
cardiac events and mortality [83]a n dw h i c hh a sb e e nl i n k e d
with poor response to treatment for depression [84–86].
Other patients who appear to be at particularly high risk
for poor outcomes include those with prominent anhedonia
(the inability to experience pleasure) [87–89]a n dt h o s ew i t h
type D personality (a personality structure characterized by
negative affectivity and social inhibition) [19], though the
latter association is controversial [90].
Thus, not only is depression common and persistent in
patients with CVD, but it also may have a negative impact
on multiple aspects of the course of cardiovascular illness,
including physical functioning, quality of life, health care
utilization, rehospitalization, and mortality.
7. Potential Mechanisms Linking Depression
and Cardiac Disease (Figure 1)
If indeed depression is an independent predictor of cardiac
illness, it is important to understand the physiologic and
behavioral underpinnings of this association. Indeed, there
are a number of mechanisms that are potentially implicated
in the connection between depression and adverse cardiac
outcomes.
7.1. Inflammation. The contribution of inflammation to the
overall development of cardiac disease—and especially to
acute cardiac events—is well documented. Inflammatory
c y t o k i n e sh a v eb e e na s s o c i a t e dw i t ha t h e r o s c l e r o t i cp l a q u e
formation, progression, and rupture; as such they are major
contributors to the pathogenesis of CAD, unstable angina,
and MI [91, 92]. Furthermore, inflammation plays a key role
in the pathogenesis of certain types of HF [93, 94]. Overall,
inflammatory cytokines (i.e., C-reactive protein (CRP) in
CAD and interleukin-6 (IL-6) in HF) have been predictive of
cardiovascular mortality and disease progression in healthy
individuals [58] and in patients with CAD [95]a n dH F[ 96–
98].
Depression also has been linked to increased levels of
c y t o k i n e s( s p e c i fi c a l l yC R P ,I L - 1 ,a n dI L - 6 ) ,b o t hi np a t i e n t s
with and without a history of cardiac disease [54, 99–101].
Two studies provide evidence that inflammation associated
with elevated depressive symptoms or MDD is associated
with the development of cardiac disease and cardiovascular
mortality. In a population cohort study of 908 patients
without known CVD, Kop and associates [58]f o u n dt h a t
depression predicted cardiovascular mortality; controlling
for inflammatory markers reduced the association by 12.7%,
suggesting that inflammation partially contributed to the
effects of depression on cardiovascular mortality. Similarly,
in a study of 559 women with suspected cardiac ischemia,4 Cardiovascular Psychiatry and Neurology
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Figure 1: Mechanisms by which depression may impact cardiac outcomes.
Vaccarino and associates found that depression predicted
cardiovascular events; controlling for inflammatory factors
(CRP,IL-6)reducedthisassociationby20%,againsuggesting
a small but meaningful contribution to the effects of depres-
sion on cardiac events [102].
There are at least two potential mechanisms by which
inflammation, depression, and cardiovascular disease may
be linked. First, neural-immune interaction may occur. In
animal models of induced fatigue, levels of the inflamma-
tory cytokine interferon alpha increase, while extracellular
levels of serotonin increase in the medial prefrontal cortex.
Furthermore, treatment with a serotonin (5HT-1A) receptor
agonist reduces the effects of fatigue [103, 104]. Hence, in
depression,reducedserotoninactionsonthesereceptorsmay
belinkedtoincreasedcytokinesandthesubsequenteffectson
cardiovascularoutcome.Second,elevatedlevelsofinflamma-
tory cytokines (e.g., interferon-gamma) are associated with
increased activity of an enzyme that degrades tryptophan (a
serotonin precursor) to kynurenine in patients with CVD
[105] .Th i si sl i k e l yt or e s u l ti nl o w e rl e v e l so fs e r o t o n i n
and may represent another mechanistic link that connects
inflammation to depression in patients with cardiac disease.
7.2. Endothelial Dysfunction. Endothelial dysfunction has
been linked to the development of ischemic CAD in patients
with atherosclerosis [106]. For example, while a normal
endothelium typically releases nitric oxide in response to
serotonin to ensure adequate blood flow through the coro-
nary arteries, in atherosclerotic arteries it fails to do so.
This results in vasoconstriction in areas of atherosclerosis
and may provide a mechanism for myocardial ischemia
and coronary thrombosis [107]. Inflammation, which has
been associated with CAD, also impairs endothelial nitric
oxide release and may represent a mechanism explaining the
findingofendothelialdysfunctionincardiacpatients[108].In
addition to its role in cardiac ischemia in patients with CAD,
endothelial dysfunction independently predicts mortality in
patients with HF [109, 110].
Depression also has been associated with impaired
endothelial function in healthy patients [111, 112], in those at
risk for CVD [113], and in those with established CVD [114].
Treatment of depression with selective serotonin reuptake
inhibitors (SSRIs) has led to improved endothelial function
in patients with depression and established CAD, further
suggesting that endothelial dysfunction may be linked to
depression’s effects on cardiac outcomes [115].
7.3. Increased Platelet Activity and Aggregation. Platelet ad-
hesion, activation, and aggregation are important com-
ponents of cardiac disease, and increased platelet activ-
ity may lead to coronary events on this basis. Serotonin
plays a key role in platelet biology through its binding
with 5-hydroxytryptamine (5-HT) receptors on platelets. In
atherosclerotic arteries, as described in the previous section,
serotonin leads to platelet aggregation [106, 107]. Further-
more, elevated levels of blood serotonin predict CAD and
future ischemic cardiac events in patients with suspected
CAD [116]. SSRIs, which theoretically deplete platelet sero-
tonin stores by inhibiting platelet uptake of serotonin, have
a l s ob e e ns h o w nt od e c r e a s ep l a t e l e ta g g r e g a t i o na n da c t i v i t y
in vitro and in patients with CAD [117, 118]. Taken together,
these findings lend credence to the theory that serotonin,Cardiovascular Psychiatry and Neurology 5
through its activity on platelet aggregation, is associated with
myocardial ischemia and other cardiac events.
Platelet dysfunction also occurs in patients suffering
from major or minor depression; depressed patients have
abnormalities in whole blood and platelet serotonin levels
[119], increased platelet serotonin receptor concentrations
[120, 121], and abnormally low platelet serotonin transporter
levels [122], suggesting that their platelets are both more
sensitive to serotonin and less able to remove it from
the bloodstream. Furthermore, there is evidence—albeit
mixed—suggesting that the platelets of depressed patients
are hyperactive [119, 123–125]. This serotonergic and platelet
dysfunction could mediate the increased risk for ischemic
events in these patients. At this stage, much less is known
abouttheassociationbetweenplatelethyperaggregabilityand
other forms of CVD.
7.4. Neurohormonal and Autonomic Nervous System Dys-
function. Neurohormonal activation may play a particularly
important role in the connection between depression and
outcomes in HF. Levels of circulating catecholamines (e.g.,
epinephrine and norepinephrine) are elevated in patients
with HF, especially in those with decompensated HF, and
higher levels of norepinephrine have been linked to greater
mortality in this illness [126, 127]. Furthermore, increases in
plasma as well as cerebrospinal fluid levels of norepinephrine
have been observed in patients with MDD to the extent of
being capable of causing increased mortality in HF [128].
Abnormalities in the hypothalamic-pituitary-adrenal (HPA)
axis may also play a substantial role, as cortisol (and aldos-
terone) are independently linked with mortality in HF, and
patients with depression have elevated levels of cortisol [98].
SuchhypercortisolemiaandotherHPA-relatedabnormalities
in depression may impact medical outcomes in other cardiac
illnesses, as these abnormalities are associated with the
development and progression of the metabolic syndrome,
a condition characterized by dyslipidemia, truncal obesity,
and insulin resistance and linked to cardiac morbidity and
mortality.
Beyond elevated levels of circulating catecholamines and
cortisol, other abnormalities in the autonomic nervous sys-
tem may also contribute to the relationship between depres-
sion and cardiac disease. Since the heart is innervated by
both the sympathetic and parasympathetic nervous systems,
the interplay between these two opposing forces helps the
heart make changes in response to stressors. Patients with
a history of ischemic heart disease or HF typically exhibit
a pattern of increased sympathetic and decreased parasym-
pathetic activity; this is manifested by decreased baroreflex
sensitivity and decreased heart rate variability (HRV) [129].
This pattern of autonomic dysfunction has been associated
with increased mortality in patients with HF [129]a n da
history of MI [129–131] and with increased rates of recurrent
AF after cardioversion [71]. In animal studies, such a pattern
ofautonomicdysfunctionwasassociatedwithincreasedrates
of ventricular fibrillation during recurrent ischemic episodes
[132] and may represent a mechanism by which autonomic
dysfunction leads to increased morbidity and mortality in
cardiac patients.
Depressed patients (with and without cardiac disease)
also have reduced HRV [133–135], suggestive of the same
imbalance between sympathetic and parasympathetic ner-
vous systems described previously. This reduction appears
to be linearly associated with depression severity, with more
severe depression resulting in greater reductions in HRV
[133]. Furthermore, patients with both CAD and depres-
sion have greater decreases in HRV compared to patients
with depression or CAD alone, suggesting that the effects
of depression and CAD on HRV are additive [135]. This
increased autonomic dysfunction in depressed patients may
therefore lead to worse cardiac outcomes in patients with
cooccurring HF.
7.5. Effects of Brain-Derived Neurotrophic Factor (BDNF) and
Related Factors. In addition to the previous mechanisms,
B D N Fm a ya l s op l a ya ni m p o r t a n tr o l ei nt h ec o n n e c -
tion between depression and cardiac outcomes. Depression
has been strongly and consistently linked to low levels of
BDNF [136], and it is thought that BDNF signaling medi-
ates the hippocampal neurogenesis that has been linked to
depression recovery [137]. Indeed, SSRI antidepressants have
been associated with increased levels of BDNF [138]a n d
with hippocampal neurogenesis [139]. BDNF also has an
important role in several physiologic processes important to
cardiovascularhealth.BDNFisexpressedbyendothelialcells,
and it leads to angiogenesis in, and survival of, endothe-
lial cells (primarily mediated via the phosphatidylinositol-
3-kinase-Akt pathway), with increased BDNF expression
during hypoxia [140]. Endothelial cells are vital to vascular
health and, as noted, endothelial function is independently
associated with cardiac outcomes.
Furthermore, BDNF expression is upregulated by neural
signals from the heart after experimentally induced MI
(interestingly, BDNF expression is increased in brain but
not heart), and such expression was linked to reduced
cardiomyocyte death and improved systolic function [141].
Such heart-brain connections are similarly seen with the
brain sigma-1 receptor (S1R) [142]. Brain S1R appears to be
associated with depression, as S1R knockout mice display
depressive phenotypes [143], and S1R agonists improve such
behavior [144]. A recent mouse model study showed that
induced heart failure was associated with reduction in brain
S1R,consistentwiththeinvestigators’hypothesisthatreduced
brain S1R exacerbates heart failure [145].
Finally, BDNF may be an important mediator of the
previously noted HPA axis effects on depression and car-
diovascular disease. The glucocorticoid receptor interacts
with the specific receptor of BDNF, TrkB, and excessive
glucocorticoid interferes with BDNF signaling [146]; there-
fore excess glococorticoids may be associated with adverse
outcomesviaBDNF-mediatedeffectsonendothelialcellsand
cardiomyocytes.
7.6. Behavioral Factors. Behavioral factors are undoubtedly
involved in the relationship between depression and cardiac
disease.Depressedpatientsarelesslikelytoengageinhealth-
promotingbehaviors,includingmaintenanceofahealthydiet6 Cardiovascular Psychiatry and Neurology
[66,147],regularexercise[66,148],adherencetomedications
[66, 147, 149], stress reduction [66], and completion of
cardiacrehabilitationprograms[150,151]followingMI.These
patients also have more difficulty lowering their cholesterol
following MI [152]. Medication nonadherence and lower
physical fitness are associated with an increased risk of car-
diovascular events in certain populations [153, 154], and this
additionally suggests that the behavioral changes associated
with depression may be associated with the progression of
CADandpoorcardiacoutcomesinpatientswithandwithout
established CVD. Fortunately, in a study of hospitalized
patients with a variety of cardiac conditions, those who
met criteria for clinical depression during admission had
improvementofadherence(todiet,exercise,andmedication)
if their depression improved following hospitalization [147].
This suggests that reduced adherence to key secondary
prevention behaviors in depressed cardiac patients may be
modifiable with treatment of the depressive symptoms.
8. Identification of Depression in
Cardiac Patients
Despite the existence of effective and safe treatments for
depression in cardiac patients, depression remains underrec-
o g n i z e da n du n d e r t r e a t e di nt h i sp o p u l a t i o n[ 155, 156]. In
one study of post-MI patients, less than 15% of depressed
patients were accurately identified as such by their treatment
teams, and only 11% received treatment with antidepressants
[155].Giventheincreasedmorbidityandmortalityassociated
with depression, it is important that these patients be more
consistently identified.
Routine screening of cardiac patients for depression is
one potential way to improve detection of depression in
this patient population. The American Heart Association
recommends such screening using the 2- and 9-item Patient
Health Questionnaires (PHQ-2 and PHQ-9, resp.) [23, 24,
157],twobriefscreeningtoolsfordepression(seeTables1and
2). The PHQ-2 inquires about the presence and frequency of
depressed mood and anhedonia, while the PHQ-9 includes
q u e s t i o n sa b o u tt h en i n ed i a g n o s t i cc r i t e r i af o rM D D( t h e
first two questions of the PHQ-9 are the PHQ-2). Both
screening tools are time-efficient and have the potential to be
integratedintostandardinpatientandoutpatientevaluations.
Furthermore, elevated scores on these scales have prognostic
value; for example, positive screens using this two-step
methodhavebeenindependentlyassociatedwithsubsequent
cardiac events in outpatients with CAD [158], and a positive
PHQ-2screenhasbeenassociatedwithsubsequentmortality
among patients with HF [159].
Regarding the operating characteristics of these tools in
cardiacpatients,alargestudyofoutpatientswithCADfound
that the PHQ-2 (with a cutoff score of 2) had sensitivity of
82%, specificity of 79%, positive predictive value of 52%, and
negative predictive value of 94% (using a contemporaneous
diagnostic interview for MDD as the gold standard), making
it a reasonably good screening tool in this cohort, especially
given its substantial brevity and excellent ability to exclude
MDD [160]. In the same cohort, PHQ-9 (using the standard
Table 1: Patient Health Questionnaire 2 (PHQ-2) [23]
∗.
Over the past two weeks, how often have you:
Not at
all
Several
days
More than
half the days
Nearly
every day
Lost interest or had
little pleasure in
doing things
01 2 3
Felt down,
depressed, or
hopeless
01 2 3
Total score = sum of two items.
PHQ-2 score ≥ 3 is suggestive of elevated symptoms of depression.
∗The PHQ-2 was developed by Drs. Robert L. Spitzer, Janet B.W. Williams,
Kurt Kroenke, and colleagues, with an educational grant from Pfizer Inc.
PHQ2 Copyright © P fi z e rI n c .A l lr i g h t sa r er e s e r v e d .
cutoff score of 10) had sensitivity of 54%, specificity of 90%,
positivepredictivevalueof61%,andnegativepredictivevalue
of88%[160].Therecommendedtwo-stepscreeningapproach
using bothitems did notappear to be superior to usingeither
tool alone for screening [160]. However, a related analysis
from the same study found that use of the two-step screening
with PHQ-2 followed by PHQ-9 enabled nearly half of the
sample to avoid undergoing the full PHQ-9 scale with few
patients with “true” depression missed as a result [158].
Clinical implementation of routine, universal screening
with the PHQ-2 or PHQ-9 has had some success but
overall mixed results. One study of this two-step screening
method found relatively high rates of completion and high
staff satisfaction among patients hospitalized on inpatient
cardiac units. However, in this case, the PHQ-2 screening
was performed by clinical nurses as part of routine care,
while the follow-up PHQ-9 was performed by a study social
worker [161]. A more complete clinical implementation of
the two-step screening resulted in substantial detection of
depression in screened patients but only modestly improved
overallrecognitionofdepressionduetoasignificantminority
of patients who did not get screened; clinical staff reported
preference for a single-stage screen instead [162]. A dif-
ferent approach to screening—once-yearly screening with
the PHQ-9—at a large veterans affairs medical center—
was associated with low rates of depression detection in
cardiac patients compared to prior studies, and reliance on
such archival screening may miss patients with newer-onset
depression in the setting of cardiac events [25].
However,thequestionofwhethertoscreenatallisavital
one. There has been much controversy about the AHA rec-
ommendations,inlargepartbecausethereisnoevidencethat
routinescreeningalonefordepression,whetherinthegeneral
populationorincardiacpatients,improvespatientoutcomes.
Critics of universal screening have, therefore, suggested that
the recommendations of the AHA be reconsidered [6, 163].
S p e c i fi cc o n c e r n sh a v ei n c l u d e dp o t e n t i a lm i s d i a g n o s i so f
patients with screening tools if patients with positive screens
do not undergo confirmatory psychiatric interviews, unnec-
essary stigma for patients who may be misdiagnosed, and
lack of evidence regarding the cost effectiveness of screening
programs [163].Cardiovascular Psychiatry and Neurology 7
Table 2: Patient Health Questionnaire 9 (PHQ-9) [24]
†.
Over the past two weeks, how often have you been bothered by the following?
Not
at all
Several
days
More than
half the days
Nearly every
day
Little interest or pleasure in doing things 0 1 2 3
Feeling down, depressed, or hopeless 0 1 2 3
Trouble falling or staying asleep or sleeping too much 0 1 2 3
Feeling tired or having little energy 0 1 2 3
Poor appetite or overeating 0 1 2 3
Feeling bad about yourself or that you are a failure or have let yourself or your family
down 01 2 3
Trouble concentrating on things, such as reading the newspaper or watching television 0 1 2 3
Moving or speaking so slowly that other people could have noticed. Or the
opposite—being so fidgety or restless that you have been moving around a lot more than
usual
01 2 3
Thoughts that you would be better off dead or of hurting yourself in some way. 0 1 2 3
If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get
along with other people?
Not difficult at all
◻
Somewhat difficult
◻
Very difficult
◻
Extremely difficult
◻
T o t a ls c o r e=s u mo f9i t e m s .
†The PHQ-9 was developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke, and colleagues, with an educational grant from Pfizer Inc. PHQ9
Copyright © Pfizer Inc. All rights are reserved.
In contrast, when depression screening is paired with
a management protocol or system of care (e.g., a care
management program) to treat depression in persons with
cardiovascular disease, there has been consistent evidence
for improved patient outcomes (including, in some studies,
improved adherence, reduced cardiac symptoms, reduced
cardiaceventsandimprovedbloodpressureandlipids)[164–
167]. Thus, some proponents of universal screening suggest
that systematic screening should be performed when there is
an available and consistent resource for treatment available
for patients who screen positive, such as collaborative care
programs [168]. Such a policy would ensure that positive-
screen patients would receive a more thorough depression
evaluation and, if depression were diagnosed, would be able
to obtain longitudinal treatment.
9. Clinical Recommendations
Regarding Assessment
Screening. Where does this leave clinicians in the assessment
of depression in cardiac patients? First, we agree with the
assertionthatdepressionscreeningshouldonlybeperformed
if there is a clear path to the patient getting treatment.
This may take several forms: a systematic care management
program, a trusted psychiatric colleague who can reliably
follow the patient, or treatment directly from the primary
m e d i c a lt e a mi ft h e yf e e lc o m f o r t a b l em a n a g i n gd e p r e s s i o n .
Without the existence of such treatment options, systematic
depression screening requires valuable resources (e.g., physi-
cian and nurse time) without clear benefit and may identify
a new and important condition without offering adequate
treatment.
When performing screening, as noted, one-time screen-
ing with the PHQ-9 appears ineffective and inefficient, while
two-stage screening with the PHQ-2 followed by the PHQ-
9 appears to allow for most nondepressed patients to end the
screeningprocessafteronlytwoquestionswhileusingallnine
DSM-IV criteria to assess positive PHQ-2 patients. In our
opinion,anapproachthatusessingle-stepscreeningwiththe
PHQ-9buthaltsscreeningwithnegativeresponsestothefirst
twoitems—theitemsthatcomposethePHQ-2—mayfindthe
best balance.
Diagnosis. In patients who screen positive, how does one
makeadiagnosisofdepression?Significantcontroversyexists
regarding the diagnosis of depression in cardiac patients.
Th i si se s p e c i a l l yt r u ei np a t i e n t sw h oh a v eh a da c u t e
cardiac events. These patients may have significant anxiety
and transiently depressed mood immediately following the
event but may not develop MDD. Furthermore, symptoms
related to the cardiac event (e.g., fatigue, poor concentration,
poor appetite) may overlap significantly with the clinical
symptoms of depression. As a result, some have argued for
lengthening the amount of time needed for a depressive
e p i s o d et ob ei d e n t i fi e di np a t i e n t sw i t ha c u t ec a r d i a ce v e n t s ,
or for excluding somatic symptoms that could be attributed
to cardiac disease.
Despite these concerns, we would recommend contin-
uing to use the DSM-IV criteria (including the 2-week
duration criterion) for the diagnosis of depression, even in
patients who have had an acute cardiac event. While one
could argue for waiting longer than 2 weeks in post-ACS
or post-CABG patients, the toxic effect of depression on
cardiac health is relatively clear, and there is some suggestion8 Cardiovascular Psychiatry and Neurology
from a recent meta-analysis that depression within 30 days
of ACS (especially if it is new-onset depression) is more
stronglyassociatedwithmortalityandcardiacmorbiditythan
premorbid depression or depression diagnosed over the first
year [69].
Furthermore, using the DSM-IV criteria for MDD
requires either loss of pleasure or depressed mood most of
the day, nearly every day, for at least 2 weeks, and patients
who meet this criterion, in addition to meeting other criteria
(whichmayincludesomaticsymptoms)inourmind,arevery
likely to have MDD, even in the face of cardiac illness.
W h i l eb e y o n dt h es c o p eo ft h i sr e v i e w ,s a f ea n de ff e c t i v e
medication(e.g.,sertraline,whichistheagentmoststudiedin
patientswithacutecardiacillness[169,170])andpsychother-
apeutic (e.g., cognitive behavioral therapy, successfully used
in patients with substantial cardiac illness [171, 172]) treat-
mentsareavailableforcardiacpatientswithMDD.Therefore,
patients who meet full criteria for MDD should be treated,
whether cardiac events are recent or remote. We hope that
systematic screening and treatment of depression in patients
with CVD can lead to improved psychiatric and medical
outcomes in this high-risk population.
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